NASH has become an epidemic in our society. It is projected that, by 2020 or 2025, the most common cause of liver transplantation in America will be related to obesity and NASH. We have now, in our research center, more than six trials where we are testing different drugs to see if we can find an effective drug that will decrease the fibrosis and prevent cirrhosis in these patients, and consequently save their lives.